Stock Financial Ratios, Dividends, Split History

HRTG / Heritage Insurance Holdings, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)469.85
Enterprise Value ($M)500.55
Book Value / Share14.30
Price / Book1.22
NCAV ($M)-1,391.39
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 25,885,004
Common Shares Outstanding 26,560,004
Weighted Average Number Of Diluted Shares Outstanding 26,798,465
Weighted Average Number Of Shares Outstanding Basic 26,798,465
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.00
Return on Assets (ROA)-0.00
Return on Equity (ROE)-0.00
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Operating Income49.53
Net Income-1.12
Cash Flow Statement (mra) ($M)
Cash From Operations7.57
Cash from Investing-7.24
Cash from Financing7.57
Identifiers and Descriptors
Central Index Key (CIK)1598665
Related CUSIPS
42727J952 42727J902

Split History

Stock splits are used by Heritage Insurance Holdings, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Heritage Insurance Holdings' (HRTG) CEO Bruce Lucas on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Heritage Insurance Holdings, Inc. (NYSE:HRTG) Q1 2018 Earnings Conference Call May 8, 2018 8:30 AM ET (1-0)

Health Insurance (HIIQ) Soars Past 80% in a Year: Here's Why

2018-04-02 zacks
That Health Insurance Innovations, Inc. (HIIQ - Free Report) stock is favored by investors, is corroborated by its agreeable share price movement. Shares of the company have soared 80.6% in a year, outperforming its industry's increase of only 3.8% and the S&P 500 index’s rally of 14.5%. With a market capitalization of $478 million, average volume of shares traded in the last three months was 0.4 million. (16-0)

5 Reasons Why Travelers Stock Fits Your Portfolio to the Tee

2018-03-28 zacks
The Travelers Companies Inc. (TRV - Free Report) has seen the Zacks Consensus Estimate for 2018 and 2019 earnings being revised upward over the last 60 days. While current-year estimates moved 0.3% north, the consensus mark for 2019 was nudged up 0.4%. This upward estimate revision reflects analysts’ optimism in the stock. Notably, the company is a leading provider of property-casualty insurance for auto, home and business. (8-0)

Avoid ProAssurance (PRA), Check These Top 3 Insurers Instead

2018-03-27 zacks
ProAssurance Corporation (PRA - Free Report) has been recently witnessing downward revisions. The stock has seen the Zacks Consensus Estimate for 2018 earnings being revised 11% downward. For 2019, our consensus estimate has moved 1.6% south. (15-0)

6 Reasons Why You Should Hold AXIS Capital in Your Portfolio

2018-03-23 zacks
AXIS Capital Holdings Limited (AXS - Free Report) is a global provider of specialty lines insurance and treaty reinsurance. Shares of this Zacks Rank #3 (Hold) property and casualty insurer have rallied 12.8% year to date, outperforming the industry’s growth of 0.3%. (10-0)

CUSIP: 42727J102